Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  recombinant interferon alfa-2b
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients with Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1404, NCI-2014-02676, NCT02506153
Chemoimmunotherapy and Vaccine Therapy in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 11-128, NCI-2015-00800, 11-128, NCT02432378
Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448
Type-1-polarized Dendritic Cell Vaccine, Interferon Alpha-2b, Rintatolimod, and Celecoxib in Treating Patients with Chemo-refractory Metastatic Colorectal Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 15-023, NCI-2016-00923, NCT02615574
Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-107, NCI-2013-01876, PRO13040314, NCT01943422
A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29322, NCI-2014-02163, 2014-000812-33, NCT02174172
Pembrolizumab and High-Dose Recombinant Interferon Alfa-2b before and after surgery in Treating Patients with Locally/Regionally Advanced or Recurrent Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 14-102, NCI-2015-00111, NCT02339324
Recombinant Interferon Alfa-2b or PEG-Interferon Alfa-2b in Treating Patients With Melanoma Undergoing Sentinel Lymph Node Biopsy
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 08-067, NCI-2011-02485, NCT00871533
Start Over